...
首页> 外文期刊>BMJ Open Respiratory Research >The Its Not JUST Idiopathic pulmonary fibrosis Study (INJUSTIS): description of the protocol for a multicentre prospective observational cohort study identifying biomarkers of progressive fibrotic lung disease
【24h】

The Its Not JUST Idiopathic pulmonary fibrosis Study (INJUSTIS): description of the protocol for a multicentre prospective observational cohort study identifying biomarkers of progressive fibrotic lung disease

机译:并非特发性特发性肺纤维化研究(INJUSTIS):描述多中心前瞻性观察队列研究的方案,以鉴定进行性纤维化肺病的生物标志物

获取原文

摘要

Introduction The Its Not JUST Idiopathic pulmonary fibrosis Study (INJUSTIS) is a multicentre, prospective, observational cohort study. The aims of this study are to identify genetic, serum and other biomarkers that may identify specific molecular mechanisms, reflecting disease endotypes that are shared among patients with progressive pulmonary fibrosis regardless of aetiology. Furthermore, it is anticipated that these biomarkers will help predict fibrotic activity that may identify patterns of disease behaviour with greater accuracy than current clinical phenotyping.Methods and analysis 200 participants with the multidisciplinary team confirmed fibrotic lung disease (50 each of rheumatoid-interstitial lung disease (ILD), asbestosis, chronic hypersensitivity pneumonitis and unclassifiable ILD) and 50 idiopathic pulmonary fibrosis participants, recruited as positive controls, will be followed up for 2 years. Participants will have blood samples, lung function tests, quality of life questionnaires and a subgroup will be offered bronchoscopy. Participants will also be given the option of undertaking blinded home handheld spirometry for the first 3 months of the study. The primary end point will be identification of a biomarker that predicts disease progression, defined as 10% relative change in forced vital capacity (FVC) or death at 12 months.Ethics and dissemination The trial has received ethical approval from the National Research Ethics Committee Nottingham (18/EM/0139). All participants must provide written informed consent. The trial will be overseen by the INJUSTIS steering group that will include a patient representative, and an independent chairperson. The results from this study will be submitted for publication in peer-reviewed journals and disseminated at regional and national conferences.Trial registration number NCT03670576.
机译:简介并非唯一的特发性肺纤维化研究(INJUSTIS)是一项多中心,前瞻性,观察性队列研究。这项研究的目的是鉴定遗传,血清和其他生物标志物,这些标志物可以鉴定特定的分子机制,从而反映出进行性肺纤维化患者共享的疾病内型,而不论病因如何。此外,预计这些生物标志物将有助于预测纤维化活性,从而可以比目前的临床表型更准确地识别疾病行为的模式。方法和分析多学科团队的200名参与者证实了纤维化性肺病(每类风湿-间质性肺病50例) (ILD),石棉沉滞症,慢性超敏性肺炎和无法分类的ILD)和50名特发性肺纤维化参与者(被招募为阳性对照),将接受2年的随访。参与者将获得血液样本,肺功能检查,生活质量调查表,并将为一个小组提供支气管镜检查。在研究的前三个月中,参与者还可以选择进行盲目家用手持式肺活量测定。主要终点将是鉴定可预测疾病进展的生物标记物,定义为在12个月时强迫肺活量(FVC)或死亡的相对变化10%。伦理与传播该试验已获得美国诺丁汉研究伦理委员会的伦理批准(18 / EM / 0139)。所有参与者必须提供书面知情同意书。该试验将由INJUSTIS指导小组进行监督,该指导小组将包括一名患者代表和一名独立主席。这项研究的结果将提交在同行评审的期刊上发表,并在区域和全国性会议上分发。注册号NCT03670576。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号